Water Conservation Overrides Osmotic Diuresis During SGLT2 Inhibition in Patients With Heart Failure

Sodium-glucose cotransporter 2 inhibitors are believed to improve cardiac outcomes due to their osmotic diuretic potential. The goal of this study was to test the hypothesis that vasopressin-driven urine concentration overrides the osmotic diuretic effect of glucosuria induced by dapagliflozin treatment. DAPA-Shuttle1 (Hepato-renal Regulation of Water Conservation in Heart Failure Patients With SGLT-2 Inhibitor Treatment) was a single-center, double-blind, randomized, placebo-controlled trial, in which patients with chronic heart failure NYHA functional classes I/II and reduced ejection fraction were randomly assigned to receive dapagliflozin 10 mg daily or placebo (1:1) for 4 weeks. The primary endpoint was change from baseline in urine osmolyte concentration. Secondary endpoints included changes in copeptin levels and solute free water clearance. Thirty-three randomized, sodium-glucose cotransporter 2 inhibitor–naïve participants completed the study, 29 of whom (placebo: n = 14; dapagliflozin: n = 15) provided accurate 24-hour urine collections (mean age 59 ± 14 years; left ventricular ejection fraction 31% ± 9%). Dapagliflozin treatment led to an isolated increase in urine glucose excretion by 3.3 mmol/kg/d (95% CI: 2.51–4.04; P < 0.0001) within 48 hours (early) which persisted after 4 weeks (late; 2.7 mmol/kg/d 95% CI: 1.98–3.51; P < 0.0001). Dapagliflozin treatment increased serum copeptin early (5.5 pmol/L 95% CI: 0.45-10.5; P < 0.05) and late (7.8 pmol/L 95% CI: 2.77–12.81; P < 0.01), leading to proportional reductions in free water clearance (early: −9.1 mL/kg/d 95% CI: −14 to −4.12; P < 0.001; late: −11.0 mL/kg/d 95% CI: −15.94 to −6.07; P < 0.0001) and elevated urine concentrations (late: 134 mmol/L 95% CI: 39.28–229.12; P < 0.01). Therefore, urine volume did not significantly increase with dapagliflozin (mean difference early: 2.8 mL/kg/d 95% CI: −1.97 to 7.48; P = 0.25; mean difference late: 0.9 mL/kg/d 95% CI: −3.83 to 5.62; P = 0.70). Physiological-adaptive water conservation eliminated the expected osmotic diuretic potential of dapagliflozin and thereby prevented a glucose-driven increase in urine volume of approximately 10 mL/kg/d · 75 kg = 750 mL/kg/d. (Hepato-renal Regulation of Water Conservation in Heart Failure Patients With SGLT-2 Inhibitor Treatment DAPA-Shuttle1; NCT04080518).